 1 
Safety and Efficacy of Initializing the 2 
Control-IQ Artificial Pancreas System Using 3 
Total Daily Insulin  4 
 5 
 6  7  8  9 
Participating Institutions  10 
University of Virginia Center for Diabetes Technology 11 
 12  13  14  15  16  17  18 
 19 
[STUDY_ID_REMOVED] 20 
Version Number: v1.4 21 
2/7/2019  22 
 23 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 2 of 48 KEY ROLES  24 
 
Protocol Sponsor/Chair   
Name, degree  Marc Breton, PhD  
Institution Name  [CONTACT_837341], degree  Melissa Schoelwer , MD  
Institution Name  [CONTACT_199562]  
 25 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 3 of 48 TABLE OF CONTENTS  26 
CHAPTER 1: BACKGROUND INFORMATION  ............................................................................................  13 27 
1.1 Introduction .......................................................................................................................... 13  28 
1.2 Rationale .............................................................................................................................. 15  29 
1.3 Potential Risks and Benefits of the Investigational Device  ................................................. 15  30 
1.3.1 Known Potential Risks ................................................................................................... 16  31 
[IP_ADDRESS] Venipuncture Risks ................................................................................................ 16  32 
[IP_ADDRESS] Fingerstick Risks .................................................................................................... 16  33 
[IP_ADDRESS] Subcutaneous Catheter Risks (CGM) .................................................................... 16  34 
[IP_ADDRESS] Risk of Hypoglycemia ........................................................................................... 16  35 
[IP_ADDRESS] Risk of Hyperglycemia .......................................................................................... 16  36 
[IP_ADDRESS] Risk of Device Reuse ............................................................................................. 17  37 
[IP_ADDRESS] Risk of Injury during Ski/Snowboarding ............................................................... 17  38 
[IP_ADDRESS] Other Risks ............................................................................................................ 17  39 
1.3.2 Known Potential Benefits .............................................................................................. 17  40 
1.4 General Considerations ........................................................................................................ 18  41 
CHAPTER 2: STUDY ENROLLMENT AND SCREENING  .............................................................................  19 42 
2.1 Participant Recruitment and Enrollment .............................................................................. 19  43 
2.1.1 Informed Consent and Authorization Procedures .......................................................... 19  44 
2.2 Participant Inclusion Criteria ............................................................................................... 19  45 
2.3 Participant Exclusion Criteria  .............................................................................................. 20  46 
2.4 Screening Procedures ........................................................................................................... 21  47 
2.4.1 Eligibility and Baseline Procedures at Screening  .......................................................... 21  48 
CHAPTER 3: STUDY SYSTEM TRAINING  ................................................................................................ . [ADDRESS_1162473]-Training Check In .................................................................................................. 23  55 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 4 of 48 CHAPTER 4: SKI ADMISSION PROCEDURES  ...........................................................................................  24 56 
4.1 Admission Check-In Procedures ......................................................................................... 24  57 
4.1.1 Participant Check-In & Verification  .............................................................................. 24  58 
4.1.2 Randomization ............................................................................................................... 24  59 
4.2 Main Admission Activities and Procedures......................................................................... 25  60 
4.2.1 General Admission Overview ........................................................................................ 25  61 
4.2.2 Device Procedures for the Participants .......................................................................... 25  62 
4.2.3 Participants’ Admission Itinerary .................................................................................. 25  63 
CHAPTER 5: AT-HOME TREATMENT & STUDY COMPLETION  ..............................................................  [ADDRESS_1162474] Admission Follow-up Phone Call .......................................................................... 28  66 
5.2 Final Study Visit .................................................................................................................. 28  67 
5.3 Early Termination Visit (If Applicable) .............................................................................. 28  68 
5.4 Unscheduled Visits .............................................................................................................. 28  69 
5.5 Participant Access to Study Device at Study Closure ......................................................... 28  70 
CHAPTER 6: STUDY DEVICES  ..................................................................................................................  30 71 
6.1 Description of the Investigational Device  ........................................................................... 30  72 
6.1.1 Insulin Pump .................................................................................................................. 30  73 
6.1.2 Continuous Glucose Monitoring .................................................................................... 30  74 
6.1.3 Blood Glucose Meter and Strips .................................................................................... 30  75 
[IP_ADDRESS] Blood Glucose Meter Testing ................................................................................ 30  76 
[IP_ADDRESS] Blood Glucose Meter Supplies .............................................................................. 30  77 
6.1.4 Blood Ketone Meter and Strips...................................................................................... 30  78 
[IP_ADDRESS] Blood Ketone Testing ............................................................................................ 30  79 
[IP_ADDRESS] Blood Ketone Meter Supplies ................................................................................ 30  80 
6.1.5 Activity Tracker  ............................................................................................................. 31  81 
6.1.6 Study Device Accountability Procedures  ...................................................................... 31  82 
6.1.7 Blood Ketone Testing .................................................................................................... 31  83 
6.2 Safety Measures ................................................................................................................... 31  84 
6.2.1 CGM Calibration ........................................................................................................... 31  85 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 5 of 48 6.2.2 System Failure ............................................................................................................... 31  86 
6.2.3 Hypoglycemia Threshold Alert and Safety Protocol  ..................................................... 31  87 
6.2.4 Hyperglycemia Threshold Alert and Safety Protocol .................................................... 32  88 
CHAPTER 7: POINT -OF-CARE TESTING  .................................................................................................. 33 89 
7.1 Point-of-Care Samples  ......................................................................................................... 33  90 
CHAPTER 8: ADVERSE EVENTS , DEVICE ISSUES , AND STOPPI[INVESTIGATOR_16442]  .............................................  34 91 
8.1 Adverse Events .................................................................................................................... 34  92 
8.1.1 Definitions...................................................................................................................... 34  93 
8.1.2 Reportable Adverse Events ............................................................................................ 35  94 
[IP_ADDRESS] Hypoglycemic Events ............................................................................................ 35  95 
[IP_ADDRESS] Hyperglycemic Events/Diabetic Ketoacidosis  ....................................................... 35  96 
8.1.3 Relationship of Adverse Event to Study Device............................................................ 36  97 
8.1.4 Intensity of Adverse Event............................................................................................. 36  98 
8.1.5 Coding of Adverse Events ............................................................................................. 36  99 
8.1.6 Outcome of Adverse Event ............................................................................................ 36  100 
8.2 Reportable Device Issues ..................................................................................................... 37  101 
8.3 Pregnancy Reporting............................................................................................................ 38  102 
8.4 Timing of Event Reporting .................................................................................................. 38  103 
8.5 Stoppi[INVESTIGATOR_2121] .................................................................................................................. 38  104 
8.5.1 Participant Discontinuation of Study Device ................................................................. 38  105 
8.5.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] ....................................................... 39  106 
8.6 Risks..................................................................................................................................... 39  107 
CHAPTER 9: MISCELLANEOUS CONSIDERATIONS  ................................................................................. 40 108 
9.1 Drugs Used as Part of the Protocol ...................................................................................... 40  109 
9.2 Prohibited Medications, Treatments, and Procedures ................................ ......................... 40  110 
9.3 Participant Compensation  .................................................................................................... 40  111 
9.4 Participant Withdrawal  ........................................................................................................ 40  112 
9.5 Confidentiality ..................................................................................................................... 40  113 
CHAPTER 10: STATISTICAL CONSIDERATION  ........................................................................................ 41 114 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 6 of 48 10.1 Statistical and Analytical Plans .......................................................................................... 41  115 
10.2 Statistical Hypotheses  ........................................................................................................ 41  116 
10.3 Sample Size........................................................................................................................ 41  117 
10.4 Outcome Measures ............................................................................................................ 41  118 
10.4.1 Primary Efficacy Endpoint .......................................................................................... 41  119 
10.4.2 Secondary Efficacy Endpoints ..................................................................................... 41  120 
[IP_ADDRESS] Safety Analyses .................................................................................................... 42  121 
10.5 Device Issues ..................................................................................................................... 42  122 
CHAPTER 11: DATA COLLECTION AND MONITORING  ...........................................................................  44 123 
11.1 Case Report Forms and Device Data ................................................................................. 44  124 
11.2 Study Records Retention ................................................................................................... 44  125 
11.3 Protocol Deviations............................................................................................................ 44  126 
CHAPTER 12: ETHICS /PROTECTION OF HUMAN PARTICIPANTS ...........................................................  [ADDRESS_1162475]  ................................................................................................................. 45  128 
12.2 Institutional Review Boards ............................................................................................... 45  129 
12.3 Informed Consent Process ................................................................................................. 45  130 
12.3.1 Consent Procedures and Documentation ..................................................................... 45  131 
12.3.2 Participant and Data Confidentiality ............................................................................ 45  132 
CHAPTER 13: REFERENCES  .....................................................................................................................  47 133 
 134 
 135 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study [ADDRESS_1162476] OF ABBREVIATIONS  136 
ABBREVIATION  DEFINITION  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CRF Case Report Form  
CGM Continuous Glucose Monitoring  
CLC Closed-Loop Control  
CSII Continuous Subcutaneous Insulin Injection  
CTR Control -to-Range  
DiAs Diabetes Assistant  
DKA Diabetic Ketoacidosis  
EC European Commission  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HCL Hybrid Closed Loop  
ID Identification  
iDCL International Diabetes Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin- on-Board  
IQR Interquartile Range  
JDRF Juvenile Diabetes Research Foundation  
NIH National Institutes of Health  
POC Point-of -Care 
QA Quality Assurance  
QC Quality Control  
RBM Risk-Based Monitoring  
SAP Sensor -Augmented Pump  
SD Standard Deviation  
TDI Total Daily Insulin  
UI User Interface  
 137 
138 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 8 of 48 Signature [CONTACT_3490] 139 
 140 
Safety and Efficacy of Initializing the Control-IQ Artificial 141 
Pancreas System Using Total Daily Insulin  142 
 143 
Protocol Identifying Number: Winter -Study -2019 144 
IDE Sponsor: Marc Breton, PhD  145 
Version  Number: v1. 4 146 
2/7/2019 147 
 148 
 149 
 
Protocol Chair/Director   
Name, degree  Marc Breton, PhD  
Signature / Date   
  
 150 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 9 of 48 SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_66674]  151 
Protocol Title:  Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System 152 
Using Total Daily Insulin  153 
Protocol Version/Date: v1.4/07FEB2019 [ADDRESS_1162477] read the protocol specified above.  In my formal capacity as a Site Principal Investigator, 155 
my duties include ensuring the safety of the study participants enrolled under my supervision 156 
with complete and timely information, as outlined in the protocol.  It is understood that all 157 
information pertaining to the study will be held strictly confidential and that this confidentiality 158 
requirement applies to all study staff at this site.  159 
This trial will be carried out in  accordance with ICH E6 Good Clinical Practice (GCP) and as 160 
required by [CONTACT_716]: [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to 161 
clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 162 
CFR Part 812). [ADDRESS_1162478] (IRB), or other approved Ethics Commi ttee, except where necessary [ADDRESS_1162479](s) to the trial participants.  167 
All key personnel (all individuals responsible for the design and conduct of this trial) have [ADDRESS_1162480] of this study are 170 
informed about their obligations in meeting the above commitments.  171 
Investigator’s Signature __________________________________ Date: _____ / _____ / _____ 172 
                      dd     mmm  yyyy 173 
Investigator’s Name: _____________________________ 174 
Site Name: _______________________________ 175 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 10 of 48 PROTOCOL SUMMARY  176 
PARTICIPANT AREA  DESCRIPTION  
Title Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas 
System Using Total Daily Insulin  
Investigational Device  Control -IQ Artificial Pancreas System with MyTDI  
Objectives The objective of the study is to assess the safety and efficacy of using the 
Control -IQ artificial pancreas system using MyTDI in a randomized 
controlled trial.  
Study Design  Up to 25 p articipants may be consented.  Up to 20 participants will 
complete a 5- day at-home data collection period prior to coming to the 
Ski Admission where they will be randomized in a 1:[ADDRESS_1162481] phase is time in target range 70-180 
mg/dL measured by [CONTACT_837335]-IQ group vs Control-IQ with 
MyTDI group over approximately [ADDRESS_1162482] 
6 months  
Sample Size  20 participants (up to 25 may be consented)  
Treatment Groups  Group 1 (HCL – Hybrid Closed Loop ): 
• Control -IQ with usual parameters  
Group 2 (MyTDI ): 
• Control -IQ with MyTDI  
Participant Duration  3 weeks  
Protocol Overview/Synopsis  After consent is signed, eligibility will be assessed.  Eligible participants will be screened and enter the data collection period for approximately 5 days at home.  Participants will then be randomized 1:1 to the use of Control -IQ vs. Control-IQ with MyTDI during a 72 hours ski admission.  
Following the admission, participants will continue the randomized treatment for approximately 5 days at home.  
 177 
 178 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 11 of 48  179 
Figure 1: Study Design 180 
Following a 5-day at-home data collection period, participants will be randomized 1:1 to use the 181 
Control-IQ system with their usual parameters or the Control -IQ system based on his/her total 182 
daily insulin.  This treatment will continue through the Ski Admission and for 5 days at home. 183 

UNIVERSITY OF VIRGINIA  
180030 – Winter Study [ADDRESS_1162483]-Admission Data 
Collection  End of 
Study  
Location  Clinic  Home Ski Lodge  Home Home 
Comment  Screen / Enroll  [ADDRESS_1162484] (if applicable)  X  X   
Physical Exam  X  X   
Vital Signs (including height/weight)  X  X   
Device Data download(s)    X  X 
Wear Study CGM , Insulin Pump, & Activity 
Tracker   X X X  
Group 1:  - Control- IQ AP (usual parameters)    X  
Group 2:  - Control- IQ AP with myTDI    X  
Review diabetes management and AEs  X X X X X 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 13 of 48 Chapter 1:  Background Information  199 
1.1 Introduction  200 
The Tandem t:slim X2 insulin pump with Control-IQ Technology is a third -generation closed - 201 
loop control (CLC) system.  The CLC is an “artificial pancreas” (AP) that uses algorithms to 202 
automatically manage insulin delivery for people with diabetes based on their blood sugar and 203 
calculated insulin needs.  This system retains the same control algorithm that was initially tested 204 
by [CONTACT_137348]’s DiAs system and then implemented in the inControl system. DiAs is described in 13 205 
IDEs (see IDEs [ADDRESS_1162485] below) and inControl is described in IDEs G160097, 206 
G160181, G150240, G140169/S010.  For complete algorithmic and clinical background, we 207 
refer to these IDEs and to a number of scientific publications that describe glycemic control 208 
outcomes and clinical impressions from the use o f these systems (see list of peer -reviewed 209 
papers in References).  This control algorithm has been implemented in two mobile platforms 210 
(DiAs and inControl) and has been tested in over [ADDRESS_1162486].  The 214 
italicized IDEs are currently using the t:slim X2  with Control-IQ Technology system proposed in 215 
this trial: 216 
1. IDE #G110095: Feasibility study of closed loop control in type 1 diabetes using heart rate 217 
monitoring as an exercise marker, approved 10/08/2011;  218 
2. IDE #G120032: Early feasibility (pi[INVESTIGATOR_2268]) study of outpatient control-to -range; 3/2/2012;  219 
3. IDE #G120210: Early feasibility study 2 of outpatient control-to -range; 10/12/2012;  220 
4. IDE #G130118: DiAs control-to -range nocturnal closed -loop camp study; 6/19/2013;  221 
5. IDE #G130121: Optimizing closed -loop control of type 1 diabetes mellitus in adolescents; 222 
6/19/2013;  223 
6. IDE# G130142: Closed loop control in adolescents using heart rate as exercise indicator; 224 
7/16/13;  225 
7. IDE #G130143: Early feasibility study of adaptive advisory/automated (AAA) control of type 226 
1 diabetes; 7/19/2013;  227 
8. IDE #G140066: Full day and night closed-loop with DiAs platform; 5/9/14.  228 
9. IDE #G140068: Unified Safety System (USS) Virginia Closed Loop versus sensor augmented 229 
pump therapy overnight in type 1 diabetes; 5/14/2014;  230 
10. IDE #G140089: Outpatient control-to -range: Safety and efficacy with day -and-night in -home 231 
use; 6/6/2014;  232 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 14 of 48 11. IDE #G140169: Unified Safety System (USS) Virginia Closed-Loop versus Sensor 233 
Augmented Pump (SAP) therapy for hypoglycemia reduction in type 1 diabetes; 10/3/2014.  234 
12. IDE #G150221: Reducing risks and improving glucose control during extended exercise in 235 
youth with T1DM: The AP Ski Camp; 11/09/2015;  236 
13. IDE #G150240: Project Nightlight: Efficacy and system acceptance of d inner/night vs. 24 hr 237 
closed loop control; 11/12/2015;  238 
14. IDE #G160047: Closed-loop in young children 5-8 years old using DiAs platform; 239 
03/29/2016; 240 
15. IDE #G160097: Clinical Acceptance of the Artificial Pancreas: the International Diabetes 241 
Closed-Loop (iDCL) Trial/Research Site Training Protocol; 06/03/16.  242 
16. IDE#G160181: PROTOCOL 1 for “Clinical Acceptance of the Artificial Pancreas: The 243 
International Diabetes Closed Loop (iDCL) Trial; 09/21/16  244 
17. IDE#G170255: Protocol 3 for “Pi[INVESTIGATOR_36733] t:slim X2 with Control-IQ Technology”; 245 
11/16/17 and IDE#G170255/S001 Protocol 3 for “Training Study of t:slim X2 with Control-IQ 246 
Technology”; 11/16/17 247 
18. IDE#G160181: Real-Time Monitoring and Glucose Control During Winter-Sport Exercise in 248 
Youth with Type 1 Diabetes: The AP Ski Camp Continued; 10/26/2017 249 
19. IDE#150240/S008: A long-term home use study, enrolling 18-70 years old TID participants 250 
since Janu ary 2018; this study is expected to be completed April 2019; 02/02/18; 251 
20. IDE#G18053 : “The International Diabetes Closed Loop (iDCL) trial: Clinical Acceptance 252 
of the Artificial Pancreas - A Pi[INVESTIGATOR_389200] t:slim X2 with Control -IQ Technology”; 253 
randomi zed controlled trial of 6 month at home closed loop system vs. sensor -augmented pump 254 
with a 3 month extension phase ; 04/13/18 ; 255 
21. IDE #G180174: “The VRIF Trial: Hypoglycemia Reduction with Automated-Insulin Delivery 256 
System”; 08/29/18.  257 
22. IDE#G180053/S007 :“The International Diabetes Closed Loop (iDCL) trial: Clinical 258 
Acceptance of the Artificial Pancreas - A Pi[INVESTIGATOR_389200] t:slim X2 with Control -IQ Technology 259 
– Extension Study ;”A 3 -month extension study for participants who completed the prior 6- 260 
month randomized controlled trial (RCT) of a closed loop system (Control-IQ) vs. sensor- 261 
augmented pump (SAP); [PENDING REVIEW BY [CONTACT_837336]] 262 
23. IDE#G180053/S008 : “The International Diabetes Closed Loop (iDCL) Trial: Clinical 263 
Acceptance of the Artificial Pancreas in Pediatrics - A Pi[INVESTIGATOR_389200] t:slim X2 with Control - 264 
IQ Technology”;  4-month parallel group randomized clinical trial with 3:[ADDRESS_1162487] of care (SC); [PENDING REVIEW BY 266 
AGENCY] 267 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study [ADDRESS_1162488] shown that use of an AP system results in increased 273 
time in the euglycemic range (70 -180 mg/dL), particularly overnight.  Challenges persist during [ADDRESS_1162489]’s home insulin parameters, which are 278 
often complicated and involve fluctuating basal rates, carbohydrate ratios, and correction factors 279 
depending on the time of the day and might not be re flective of his/her true insulin needs. The 280 
CLC system allows the user to receive feedback on his/her average total daily insulin needs with 281 
a report of Total Daily Insulin (TDI). Clinicians can in turn use TDI to easily determine insulin [ADDRESS_1162490] formulas to calculate the optimal basal rate, carbohydrate ratio, 283 
and correction factor as follows:  284 
• Basal rate = TDI/48 (half of the daily insulin needs are  delivered in the form of basal 285 
insulin) 286 
• Correction factor (CF) = 1650/TDI  287 
• Carb ratio (CR) = 450/TDI (to be used for lunch and dinner)  288 
• Carb ratio for breakfast: to achieve a 20% increase in insulin we will use the following 289 
carb ratio: CR bkfst=CR/1.2  (to account for increased insulin needs in the morning)  290 
The system can then m odify the insulin to keep blood glucose in range as necessary.  291 
This trial aims to demonstrate the safety and feasibility of using MyTDI to determine insulin 292 
parameters on the CLC AP system t :slim  X2 with Control-IQ technology for use both at ski 293 
camp and at home in adolescent patients with type 1 diabetes.    294 
Primary Specific Aim:  295 
To assess the safety and feasibility of using insulin parameters as determined by [CONTACT_837337] 296 
normal outpatient conditions  in the t:slim X2 with Control -IQ Technology AP system.  297 
Secondary Specific Aim s: 298 
To assess the safety and feasibility of using insulin parameters as determined by [CONTACT_837337] 299 
intense exercise outpatient conditions in the t:slim X2 with Control -IQ Technology AP system.  300 
1.3 Potential Risks and Benefits of the Investigational Device 301 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data 302 
are handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are 303 
always a risk in participants with type 1 diabetes and participants will be monitored for this.  304 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 16 of 48 1.3.1 Known Potential Risks  305 
[IP_ADDRESS]  Venipuncture Risks  306 
A hollow needle/plastic tube will be placed in the arm for taking blood samples. Blood draws 307 
can cause some common reactions like pain, bruising, or redness at the sampling site.  Less 308 
common reactions include bleeding from the sampling site, formation of a small blood clot or 309 
swelling of the vein and surrounding tissues, and fainting. 310 
[IP_ADDRESS]  Fingerstick Risks  [ADDRESS_1162491] for several weeks.  315 
The risk of local infection is less than 1 in 1000.  This should not be a significant contributor to 316 
risks in this study as fingersticks are part of the usual care for people with diabetes.  317 
[IP_ADDRESS]  Subcutaneous Catheter Risks (CGM)  318 
Participants using the CGM will be at low risk for developi[INVESTIGATOR_007] a local skin infection at the site of 319 
the sensor needle placement.  If a catheter is left under the skin for more than 24 hours, it is 320 
possible to get an infection where it goes into the skin, with swelling, redness and pain.  There 321 
may be bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 322 
risk). [ADDRESS_1162492] a small portion of the sensor under the skin that may cause redness, swelling or pain at the 325 
insertion site.  The participant should be further instructed to notify the study coordinator 326 
immediately i f this occurs. 327 
[IP_ADDRESS]  Risk of Hypoglycemia  328 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a 329 
low blood sugar (hypoglycemia).  The frequency of hypoglycemia should be no more and [ADDRESS_1162493] as at home, there is the possibility of fainting or 332 
seizures (convulsions) and that for a few days the participant may not be as aware of symptoms 333 
of hypoglycemia.  A CGM functioning poorly and significantly over-reading glucose values 334 
could lead to inappropriate insulin delivery. 335 
[IP_ADDRESS]  Risk of Hyperglycemia  336 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 337 
extended  period or if the pump or infusion set is not working properly.  A CGM functioning 338 
poorly and significantly under-reading glucose values could lead to inappropriate suspension of 339 
insulin delivery. 340 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 17 of 48 [IP_ADDRESS]  Risk of Device Reuse  341 
The study CGM system is labeled for single use only. The sensor (the component of the system 342 
that enters the skin) will be single use only. The transmitter and receiver may be reused during [ADDRESS_1162494] approved these 346 
devices for single use and that by [CONTACT_28040], bloodborne pathogens 347 
(i.e. Hepatitis B) may be spread through the use of multiple users. 348 
The study insulin pump is labeled for single-patient use. During the study, this device may be 349 
reused after cleaning adhering to a hospi[INVESTIGATOR_307]-approved cleaning procedure. All infusion set 350 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.)  351 
Participants will be informed that FDA or relevant national authorities typi[INVESTIGATOR_498295] 352 
insulin pump device for single use and that by [CONTACT_28040], bloodborne 353 
pathogens (i.e. Hepatitis B) may be spread through the use of multiple users. 354 
The study blood glucose meter and blood ketone meter are labeled for single-patient use. 355 
During the study, only one person can use each device as there are rare risks that bloodborne 356 
pathogens (i.e. Hepatitis B) may be spread through the use of multiple users. 357 
[IP_ADDRESS]  Risk of Injury during Ski/Snowboarding  358 
Bruising, dislocations, sprains, and fractures of the leg and shoulders are very common whi le 359 
participating in these activities .  360 
[IP_ADDRESS]  Other Risks  361 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 362 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  363 
If these reactions occur, different adhesives or “under-tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, 364 
etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_91101] 365 
medication may be required.  366 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump 367 
infusion sites are inserted under the skin.  It is possible that any part that is inserted under the 368 
skin may cause an infection.  These occur very infrequently, but, if an infection was to occur, 369 
oral and/or topi[INVESTIGATOR_27996].  The risk of skin problems could be greater if you use 370 
a sensor for longer than it is supposed to be used.  Therefore, participants will be carefully 371 
instructed about proper use of the sensor. 372 
Data downloaded from the CGM, pump, and the home glucose and ketone meter will be 373 
collected for the study as measures of diabetes self -management behaviors.  Some people 374 
may be uncomfortable with the researchers' having such detailed information about their daily 375 
diabetes habits.  376 
1.3.2 Know n Potential Benefits  377 
One purpose of this research is to reduce the frequency of hypoglycemia and severe 378 
hypoglycemic events  in relation to performing a winter sport exercise (skiing/snowboarding). 379 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study [ADDRESS_1162495] their origin in the Declaration of Helsinki, with 387 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  [ADDRESS_1162496] that the closed loop 393 
system is experimental.  Therefore, an investigational device exempt ion (IDE) from the U.S. 394 
Food and Drug Administration (FDA) is required to conduct the study. 395 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 19 of 48 Chapter 2:  Study Enrollment and Screening  396 
2.1 Participant Recruitment and Enrollment  397 
Enrollment will proceed with the goal of having 20 parti cipants , age 12-18 years, enter the 398 
randomized trial, with the expectation that 20 participants will complete the randomized trial.  A 399 
maximum of 25 individuals may be enrolled into screening for the study in order to achieve this 400 
goal. 401 
Participants will be recruited at the University of Virginia.  402 
2.1.1 Informed Consent and Authorization Procedures  403 
Potential eligibility may be assessed as part of a routine-care examination.  Before completing 404 
any procedures or collecting any data that are not part of usual care, written informed consent 405 
will be obtained.  406 
For potential study participants ≥ 18 years old, the study protocol will be discussed with the 407 
potential study participant by [CONTACT_464].  The potential study participant will be given the 408 
Informed Consent Form to read.  Potential study participants will be encouraged to discuss the 409 
study with family members and their personal physicians(s) before deciding whether to 410 
participate in the study.  411 
For potential participants under 18 years of age, a parent/legal guardian  (referred to subsequently 412 
as “parent”) will be provided with the Informed Consent Form to read and will be given the 413 
opportunity to ask questions.  Potential participants meeting the IRB’s minimum age of assent 414 
will be given a Child Assent Form to read an d discuss with his/her parents and study personnel.  415 
If the parent and child agree to participate, the Informed Consent Form and Child Assent Form 416 
will be signed.  A copy of the consent form will be provided to the participant and his/her parent 417 
and anothe r copy will be added to the participant’s study record.  [ADDRESS_1162497] meet all of the following inclusion criteria in order to be eligible to participate 421 
in the study. 422 
• Criteria for documented hyperglycemia (at least [ADDRESS_1162498] be met):  423 
o Clinical diagnosis of type 1 diabetes (C-peptide levels and antibody 424 
determinations are not required)  425 
o Diagnosis of type 1 diabetes is based on the investigator’s  judgement 426 
• Criteria for requiring insulin at diagnosis (both criteria must be met):  427 
o Daily insulin therapy for ≥ 6 months  428 
o Insulin pump therapy for ≥ 3 months  429 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 20 of 48 • Age 12-18 years 430 
• Currently using no insulins other than one of the following rapid -acting insulins at the 431 
time of enrollment: insulin lispro (Humalog), insulin aspart (N ovolog), or insulin 432 
glulisine (Api[INVESTIGATOR_27976]). If using glulisine, subject must be willing to switch to lispro or aspart. 433 
• Treatment with any non -insulin glucose-lowering agent (including GLP-1 agonists, 434 
Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas, and 435 
naturaceuticals) is permitted if stable on current dose for at least 3 months.  436 
• Willingness to wear a continuous glucose sensor and physiological monitor for the 437 
duration of the study. 438 
• For females, not pregnant or breastfeeding.  Female subjects who are sexually active 439 
should agree to use birth control during the study. 440 
2.3 Participant Exclusion Criteria  441 
Individuals meeting any of the foll owing exclusion criteria at baseline will be excluded from 442 
study participation. 443 
• Diabetic ketoacidosis in the past 6 months  444 
• Hypoglycemic seizure or loss of consciousness in the past 6 months 445 
• History of seizure disorder 446 
• History of any heart disease including  coronary artery disease, heart failure, or 447 
arrhythmias 448 
• History of altitude sickness  449 
• Chronic pulmonary conditions that could impair oxygenation 450 
• Cystic fibrosis 451 
• Current use of oral glucocorticoids, beta-blockers or other medications, which in the 452 
judgement of the investigator, would be a contraindication to participation in the study.  453 
• History of ongoing renal disease (other than microalbuminuria). 454 
• Subjects requiring intermediate or long -acting insulin (such as NPH, Detemir, or 455 
Glargine). 456 
• Pregnancy 457 
• Presence o f a febrile illness within 24 hours of the Ski Admission. 458 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 21 of 48 • Medical or psychiatric conditions that in the judgement of the investigator might interfere 459 
with the completion of the protocol such as:  [ADDRESS_1162499] 6 months  461 
o Uncontrolled adrenal insufficiency  462 
o Alcohol abuse 463 
2.4 Screening Procedures  464 
After informed consent has been signed, a potential participant will be evaluated for study 465 
eligibility through the elicitation of a medical history, performance of a physical examination 466 
by [CONTACT_253287] (i.e. licensed medical physicians and nurse practitioners) and local laboratory 467 
testing if needed to screen for exclusionary medical conditions.  468 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 469 
date per investigator discretion.  470 
2.4.1 Eligibility and Baseline Procedures at Screening  471 
The following procedures and testing will be performed to ensure eligibility:  472 
• Inclusion and exclusion criteria assessed  473 
• Demographics (date of birth, sex, race and ethnicity) 474 
• Contact [CONTACT_3031]  475 
• Medical history  476 
• Concomitant medications  and supplements 477 
• Pregnancy Test for women of child-bearing potential (urine) 478 
• Blood draw 479 
• Hemoglobin A1c measured using the DCA2000 or comparabl e point of care device or local 480 
lab; a lab result within 3 months of enrollment may be used at the investigator’s discretion  481 
• Physical examination including height, weight, and vital signs (physical exam from the last 482 
12 months may be used at the investigat or’s discretion) 483 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 22 of 48 Chapter 3:  Study System Training  484 
3.1 Study Equipment Training  485 
This phase may begin immediately after enrollment is complete.  Participants will be trained and 486 
begin using the Control-IQ system to manage their glucose levels and insulin delivery at the 487 
conclusion of the training session.  Participants will discontinue the use of their existing CGM 488 
and insulin pump, if applicable.  Training on use of the activity tracker (i.e. Fitbit) will also 489 
occur.  Participants will use the study equipment (study insulin pump, study CGM, study activity 490 
tracker) to collect data for approximately [ADDRESS_1162500] one of their parents or 492 
care providers, using the Dexcom or Tandem app. 493 
3.1.1 Initiation of CGM  494 
The participant will be provided with sensors and instructed to use the study CGM on a daily 495 
basis. Training will be provided to participants not experienced with CGM use as to how to use 496 
the CGM in real -time to make management decisions and how to review the data after an upload 497 
for retrospective review. Participants using a personal CGM prior to the study will discontinue 498 
the personal CGM beginning in this period. 499 
The par ticipant will be observed placing the sensor. The study CGM user’s guide will be 500 
provided for the participant to take home.  501 
3.1.2 Initiation of Study Pump  502 
Participants will complete training on the study pump as detailed below.  503 
• The participant will be fully instructed on the study insulin pump. A qualified system trainer 504 
(i.e. Certified Diabetes Educator) will conduct the training and in particular discuss [ADDRESS_1162501] and correction boluses. Additional topi[INVESTIGATOR_418073]: infusion 507 
site initiation, cartridge/priming procedures, setting up the pump, charging the pump, 508 
navigation through menus, bolus procedures including stoppi[INVESTIGATOR_007] a bolus, etc. 509 
• The study team will assist the participant in study pump infusion site initiation and will start 510 
the participant on the study pump. The study pump will be programmed with the 511 
participant’s usual basal rates and pump parameters. The participant’s personal pump will be 512 
removed. 513 
• The participant will be supervised with the study pump during at least one meal or snack 514 
bolus to ensure participant understanding of the pump features. 515 
• The participant will be encouraged to review the literature provided with the pump and [ADDRESS_1162502] additional 519 
information about movement and heart rate.  The activity tracker can be removed during bathing.  520 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 23 of 48  521 
3.1.4 Blood Glucose and Ketone Testing  522 
Participants will receive supplies for blood glucose and ketone testing.  523 
• Blood glucose testing 524 
 Participants will be provided with a study blood glucose meter  and test strips.  525 
 All study blood glucose meters will be QC tested with at least two different 526 
concentrations of control solution if available during all office visits.  A tested meter 527 
will not be used in a study if it does not read within the target range at each 528 
concentration per manufacturer labeling.   529 
 Participants wi ll be reminded to use the study blood glucose meter for all fingerstick 530 
BGs during the study. 531 
 Participants will be given guidelines for treatment of low or high blood glucose.  532 
• Blood ketone testing  533 
 Participants will be provided with a study blood ketone meter  and test strips.  534 
 All study blood ketone meters will be QC tested with at least two different 535 
concentrations of control solution if available during all office visits.  A tested meter 536 
will not be used in a study if it does not read within the target range at each 537 
concentration per manufacturer labeling.     538 
 Participants will be instructed to perform blood ketone testing as described in 539 
section  6.2.4  540 
 Participants will be given guidelines for treatment of elevated blood ketones  541 
• Participants will be required to have a home glucagon emergency kit. Participants who [ADDRESS_1162503] the participants approximately 48 -72 hours after initiation of the 545 
study equipment to discuss: 546 
• Questions or concerns about the study and/or equipment 547 
• Ensure proper use of study equipment 548 
• Ask about the occurrenc e of any events, including adverse events   [ADDRESS_1162504] information of multiple team members.  If 551 
there is a medical emergency that requires immediate medical attention, participants will be 552 
instructed to call emergency medical services (e.g. 911).   553 
  554 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 24 of 48  555 
Chapter 4:  Ski Admission Procedures  556 
4.1 Admission Check -In Procedures  557 
4.1.1 Participant Check -In & Verification  558 
At time of check -in, participants will undergo the following procedures/tests:  559 
• Vital signs measured  560 
• A fever or had a significant illness within 24 -hours of admission will disqualify 561 
participant from study 562 
• A fingerstick blood glucose and fingerstick ketone measurement will be obtained  563 
• Female subjects of childbearing potential will be required to complete a urine pregnancy [ADDRESS_1162505]. If positive, participant will be discontinued from the study.  565 
• Study device s and  insertion sites will be inspected  566 
• Confirm that the participant brought his/her personal insulin, study supplies, and regular 567 
medications.   568 
• Participants will be asked to perform a blood ketone fingerstick.  If ketones > 1.5 mmol/L, 569 
study staff should treat with oral hydration and, if needed, the Glycemic Treatment 570 
Guidelines wi ll be followed; ketones will be re-checked every hour until ≤ 1.5 mmol/L.  571 
The participant will be able to begin participation in the winter sport activities once the 572 
CGM reads between 80-300 mg/dL and ketones are ≤ 1.5 mmol/L.  573 
• Data from the participant’s in sulin pumps will be reviewed and/or downloaded for a [ADDRESS_1162506] in age and HbA1c value will be paired and then randomized – one member 580 
of each block randomly assigned to each of the two treatment groups. 581 
Participants who randomize to Group 1 Hybrid Closed Loop (HCL) will have no modifications [ADDRESS_1162507] 20% reduction in insulin to account for 583 
increased exercise while at ski camp .  Participants who randomize to Group 2 (MyTDI) will have 584 
modifications to their insulin pump p arameters to take into consideration his/her total daily 585 
insulin  along with the 20% reduction in insulin during ski camp.   586 
The MyTDI adjustment s will be as follow s: 587 
• A single basal rate equal to TDI/48 will be implemented ac ross the whole day 588 
• A single correction factor of 1650/T DI will be implemented across the whole day  589 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 25 of 48 • Carbohydrate ratios will be set at:  590 
o 0000-04:00 CR=450/TDI 591 
o 0400-1100 CR=450/TDI)/1.2 592 
o 1100-0000 CR=450/TDI 593 
TDI will be reduced by 20% of the internal Control-IQ estimation total daily dose ; if not [ADDRESS_1162508] 5 days will be used.  595 
Aside from the insulin pump settings , all other study procedures are identical in the two 596 
treatment groups during the Admission and the second at-home portion of the study. 597 
4.2 Main Admission Activities and Procedures  598 
4.2.1 General Admission Overview  599 
During the entire admission, participants will be m onitored remotely by [CONTACT_3476].  Study 600 
team members trained in all protocol interventions (including the hypo and hyperglycemia safety 601 
protocols) will be skiing with the participants, with each member remotely connected to the 602 
participants CGM data.  In addition, a study team member trained in all protocol and glycemic 603 
treatment guidelines procedures will be available at a central location in the resort.   604 
All recreational activities will be managed by ‘Riding on Insulin’ with study staff supervision. [ADDRESS_1162509] all equipment  with them at all times, including a cell phone (personal or 612 
study-provided) with the Dexcom Follow App.  Participants will be asked to respond to both [ADDRESS_1162510] as per the Glycemic Treatment Guidelines.  615 
Participants may be re- educated as needed by [CONTACT_5984], who will be available at all times to 616 
assure proper use of all study equipment. 617 
4.2.3 Participants’ Admission Itinerary  618 
Participants will generally follow the below schedule during the Admission:  619 
Evening of Check-in  620 
1500-1900: Check-In & Randomization.  Participants will undergo the check -in procedures 621 
outlined in section 4.1.  Study team will download the study equipment.  622 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 26 of 48 1900-2000: Dinner.  The study CGM will be used to determine the pre-meal bolus.  623 
2000-2300: Evening Activity. 624 
Day 1 625 
0800-0900: Breakfast.  The study CGM will be used to determine the pre-meal bolus.  626 
0900-1200: Morning Ski Activity.  Participants will begin the morning ski session if his/her 627 
CGM reads >100 mg/dL.  If ≤ 100 mg/dL, the Glycemic Treatment Guidelines will be follow ed 628 
until cleared to begin activity.  629 
1200-1300: Lunch.  The study CGM will be used to determine the pre-meal bolus.  630 
1300-1600: Afternoon Ski Activity.  Participants will begin the afternoon ski session if his/her 631 
CGM reads >100 mg/dL.  If ≤ 100 mg/dL, the G lycemic Treatment Guidelines will be followed 632 
until cleared to begin activity.  633 
1600-1800: Quiet time  634 
1800-2000: Dinner.  The study CGM will be used to determine the pre-meal bolus.  635 
2200: Bedtime Snack.  The study CGM will be used to determine the pre-meal bolus.  636 
2030-2300: Evening Activity.   637 
Day 2 638 
0800-0900: Breakfast.  The study CGM will be used to determine the pre-meal bolus.  639 
0900-1200: Morning Ski Activity.  Participants will begin the morning ski session if his/her 640 
CGM reads >100 mg/dL.  If ≤  100 mg/dL, the Glycemic Treatment Guidelines will be followed 641 
until cleared to begin activity.  642 
1200-1300: Lunch.  The study CGM will be used to determine the pre-meal bolus.  643 
1300-1600: Afternoon Ski Activity.  Participants will begin the afternoon ski session if his/her 644 
CGM reads >100 mg/dL.  If ≤ 100 mg/dL, the Glycemic Treatment Guidelines will be followed 645 
until cleared to begin activity.  646 
1600-1800: Quiet time  647 
1800-2000: Dinner.  The study CGM will be used to determine the pre-meal bolus.  648 
2200: Bedtime S nack.  The study CGM will be used to determine the pre-meal bolus.  649 
2030-2300: Evening Activity.   650 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 27 of 48 Day 3 651 
0800-0900: Breakfast.  The study CGM will be used to determine the pre-meal bolus.  652 
0900-1200: Checkout and discharge to parents.  The study staff will adjust all participants’ 653 
insulin pumps to remove the 20% rate reduction with the cessation of ski activity and in 654 
anticipation of the at-home treatment period.  Participants will be discharged if appropriate and 655 
in accordance with the Glycemic Treatment Guidelines.  Participants will be discharged with the 656 
study equipment and any supplies needed for the at-home treatment period.   657 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 28 of 48 Chapter 5:  At-Home Treatment & Study Completion  [ADDRESS_1162511] the participants approximately 24 -48 hours after they are discharged 667 
from the Ski Admission to discuss: 668 
• Questions or concerns about the study and/or equipment 669 
• Ensure proper use of study equipment 670 
• Ask about the occurrence of any events, including adverse events   [ADDRESS_1162512] information of multiple team members.  If 673 
there is a medical emergency that requires immediate medical attention, participants will be 674 
instructed to call emergency medical services (e.g. 911).   675 
5.2 Final Study Visit  676 
The final study visit may be performed remotely (phone) or in-person.  After approximately [ADDRESS_1162513] not been reported 682 
to the study team.   683 
5.3 Early Termination Visit (If Applicable)  [ADDRESS_1162514] unscheduled visits du ring the study period if required for additional device 688 
training or other unanticipated needs per the study investigator discretion. 689 
5.5 Participant Access to Study Device at Study Closure 690 
Participant will return all investigational study devices and supplies (insulin pump, CG M, 691 
activity tracker, and  related supplies) at study closure.  Participant may keep the study ketone 692 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 29 of 48 meter and study glucometer if these devices are not marked for investigational use only  after the 693 
study team has downloaded all data from the devices . 694 
  695 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 30 of 48 Chapter 6:  Study Devices  696 
6.1 Description of the Investigational Device 697 
6.1.1 Insulin Pump  698 
The study system will include the Tandem t:slim X2 with Control -IQ Technology.   699 
6.1.2 Continuous Glucose Monitoring  700 
The study CGM will include Dexcom G6 transmitter and sensors when using the Tandem t:slim [ADDRESS_1162515] once every 10 days. 702 
6.1.3 Blood Glucose Meter and Strips 703 
Blood glucose levels will be measured using the study’s blood glucose meter (glucometer) and 704 
the CGM device will be calibrated if needed using the study glucometer and  strips in accordance 705 
with the manufacturer’s labeling. 706 
[IP_ADDRESS]  Blood Glucose Meter Testing  707 
• All study blood glucose meters will be QC tested with at least two different concentrations of 708 
control solution if available during all office visits.  A tested meter will not be used in a study 709 
if it does not read within the target range at each concentra tion per manufacturer labeling.   710 
• Participants will be reminded to use the study blood glucose meter for all fingerstick blood 711 
glucose measurements.  712 
[IP_ADDRESS]  Blood Glucose Meter  Supplies  713 
• Participants will be provided all necessary supplies during the study.   714 
• Participants will permitted to keep these devices at the conclusion of the study.  715 
6.1.4 Blood Ketone Meter and Strips 716 
Blood ketone levels will be measured using the Abbott Precision Xtra Ketone M eter and strips in 717 
accordance with the manufacturer’s labeling.  The blo od glucose meter component of the 718 
Precision Xtra device will not be used.  719 
[IP_ADDRESS]  Blood Ketone Testing  720 
• All study blood ketone meters will be QC tested with at least two different concentrations of 721 
control solution if available during all office visits.  A tested m eter will not be used in a study 722 
if it does not read within the target range at each concentration per manufacturer labeling.   723 
• Participants will be instructed on how to perform blood ketone testing. 724 
• Participants will be given guidelines for treatment of elevated blood ketones.  725 
[IP_ADDRESS]  Blood Ketone Meter Supplies 726 
• Participants will be provided all necessary supplies during the study.   727 
• Participants will permitted to keep these devices at the conclusion of the study.  728 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 31 of 48 6.1.5 Activity Tracker  729 
• Participants will be trained on the study activity tracker that will be used to collect additional 730 
information about movement and heart rate.  731 
• Participants will be asked to wear the device during the entire study. The monitor can be 732 
removed during bathing. 733 
6.1.6 Study Device Accountability Pro cedures  734 
Device accountability procedures will be detailed in the site procedures manual.  735 
6.1.7 Blood Ketone Testing  736 
• All study blood ketone meters will be QC tested with at least two different concentrations of 737 
control solution if available during all office visi ts.  A tested meter will not be used in a study 738 
if it does not read within the target range at each concentration per manufacturer labeling.   739 
• Participants will be instructed on how to perform blood ketone testing. 740 
• Participants will be given guidelines for  treatment of elevated blood ketones.  [ADDRESS_1162516] insulin. If the CGM is not connected, the 748 
system will revert to usual function of the pump and deliver insulin with the insulin dosing 749 
parameters programmed in the system for that individual. Resumption of Closed-Loop will 750 
occur automatically once CGM signal is available again.  751 
If the study system is unable to activate Control-IQ for any reason, the pump will automatically 752 
revert to preprogrammed basal insulin delivery without any need for instruction from the user. 753 
If the t:slim X2 detects a system error that does not allow the pump to operate, the Malfunction [ADDRESS_1162517] Tandem Techn ical Support 755 
via the study team.  756 
6.2.3 Hypoglycemia Threshold Alert and Safety Protocol  757 
During the course of the study, participants will be permitted to change the CGM low glucose 758 
threshold alert setting  on their device or mobile app , but will be instructed to choose a value no 759 
less than 60 mg/dL.  760 
The t:slim X2 with Control -IQ system will issue a predictive hypoglycemia alert (Control-IQ 761 
Low Alert) when the system predicts BG <70 mg/dL within the next 15  minutes (<80 mg/dL 762 
when exercise mo de is activated ). 763 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 32 of 48 If the participant receives a Control-IQ Low Alert , a message appears on the UI that is 764 
accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_28024] [ADDRESS_1162518] blood sugar and treat with carbs. 767 
If a participant’s CGM reading is <80 mg/dL, the Glycemic Treatment Guidelines will be 768 
followed. 769 
6.2.4 Hyperglycemia Threshold Alert and Safety Protocol  770 
During the course of th e study, participants will be permitted to change the CGM high glucose 771 
threshold alert setting  on their device or mobile app, but will be instructed to choose a value no 772 
greater than 300 mg/dL.  773 
The t:slim X2 with Control -IQ system will issue a predictive h yperglycemia alert (Control-IQ 774 
High Alert) when the system has increased insulin delivery, but detects a CGM value above 200 775 
mg/dL and does not predict the value will decrease in the next 30 minutes.  776 
If the participant receives a Control-IQ High Alert, a m essage appears on the UI that is 777 
accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_28024] [ADDRESS_1162519] blood glucose. 780 
If a participant’s CGM reading is >300 mg/dL for over 2 hours or ≥400 mg/dL at any point, the 781 
Glycemic Treatment Guidelines will be followed.  782 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 33 of 48 Chapter 7:  Point -of-Care  Testing  783 
7.1 Point -of-Care  Samples 784 
1. HbA1c:  785 
• Performed locally at the Screening visit or a lab result that was completed within 2 weeks 786 
prior to the Screening visit.  787 
2. Urine Pregnancy: 788 
• Performed locally for females of child -bearing potential at the Screening visit and prior to the 789 
start of the S ki Admission. 790 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 34 of 48 Chapter 8:  Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869]  791 
8.1 Adverse Events 792 
8.1.1 Definitions  793 
Adverse Event (AE): Any untoward medical occurrence in a study participant, irrespective of the 794 
relationship between the adverse event and the device(s) under investigation (see section 8.1.2 795 
for reportable adverse events for this protocol). 796 
Serious Adverse Event (SAE): Any untoward medical occurrence that:  797 
• Results in death.  798 
• Is life-threatening; (a non-life-threatening event which, had it been more severe, might have 799 
become life -threatening, is not necessarily considered a serious adverse event).  800 
• Requires inpatient hospi[INVESTIGATOR_1081]. 801 
• Results in persistent or significant disability/incapacity or substantial disruption of the ability [ADDRESS_1162520] normal life functions (sight threatening). 803 
• Is a congenital anomaly or birth defect. 804 
• Is considered a significant medical event by [CONTACT_13656] (e.g., 805 
may jeopardize the participant or may require medical/su rgical intervention to prevent one of 806 
the outcomes listed above).  [ADDRESS_1162521] (UADE):  Any serious adverse effect on health or safety or [ADDRESS_1162522], 809 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 810 
investigational plan or application (including a supplementary plan or application), or any other 811 
unanticipated serious problem associated with a device that relates to the rights, safety, or 812 
welfare of participants (21 CFR 812.3(s)). [ADDRESS_1162523] (ADE):  Any untoward medical occurrence in a study participant which [ADDRESS_1162524] contributed . 815 
Device Complaints  and Malfunctions: A device complication or complaint is something that 816 
happens to a device or related to device performance, whereas an adverse event happens to a 817 
participant.  A device complaint may occur independently from an AE, or along with an AE.  818 
An AE may occur without a device complaint or there may be an AE related to a device 819 
complaint.  A device malfunction is any failure of a device to meet its performance specifications 820 
or otherwise perform as intended.  Performance specifications include all  claims made in the 821 
labeling for the device.  The intended performance of a device refers to the intended use for 822 
which the device is labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, sites 823 
will not be asked to distinguish between device complaints and malfunctions. 824 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study [ADDRESS_1162525] medical occurrence that 826 
meets one of the following criteria:  [ADDRESS_1162526] as defined in section 8.1.1, unless excluded from reporting in 829 
section 8. 830 
3. An Adverse Event occurring in association with a study procedure 831 
4. Hypoglycemia meeting the definit ion of severe hypoglycemia as defined below  832 
5. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, a hyperglycemic or [ADDRESS_1162527].  Skin reactions from sensor placement 836 
are only reportable if severe and/or required treatment.  837 
Pregnancy occurring during the study will not be considered an adverse event. 838 
[IP_ADDRESS]  Hypoglycemic Events  [ADDRESS_1162528] is only reportable as an adverse 840 
event when the following definition for severe hypoglycemia is met: the event required 841 
assistance of another person due to altered consciousness, and required another person to actively 842 
administer carbohydrate, glucagon, or other resuscitative actions.  This means that the participant 843 
was impaired cogn itively to the point that he/she was unable to treat himself/herself, was unable 844 
to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure 845 
or coma.  These epi[INVESTIGATOR_418080] 846 
coma.  If plasma glucose measurements are not available during such an event, neurological 847 
recovery attributable to the restoration of plasma glucose to normal is considered sufficient 848 
evidence that the event was induced by a low plasma glucose concentration.  849 
[IP_ADDRESS]  Hyperglycemic Events/Diabetic Ketoacidosis  [ADDRESS_1162529] is only reportable as an adverse 851 
event when one of the following four criteria is met:  852 
• the event involved DKA, as defined by [CONTACT_3467] 853 
(DCCT) and described below 854 
• evaluation or treatment was obtained at a health care provider facility for an acute event 855 
involving hyperglycemia or ketosis 856 
• blood ketone level ≥1.5 mmol/L and communication occurred with  a health care provider at 857 
the time of the event  858 
• blood ketone level ≥3.0 mmol/L, even if there was no communication with a health care 859 
provider 860 
Hyperglycemic events are classified as DKA if the following are present:  861 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 36 of 48 • Symptoms such as polyuria, polydipsia, nausea, or vomiting; 862 
• Serum ketones ≥ 1.5 mmol/L or large/moderate urine ketones;  863 
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and 864 
• Treatment provided in a health care facility  865 
All reportable Adverse Events —whether volunteered b y the participant, discovered by [CONTACT_3449] [ADDRESS_1162530], or other 867 
means —will be reported on an adverse event form online.  Each adverse event form is reviewed [ADDRESS_1162531] been caused by [CONTACT_19911].  873 
8.1.4 Intensity of Adverse Event  874 
The intensity of an adverse event will be rated on a three point scale: (1) mild, (2) moderate, or 875 
(3) severe.  It is emphasized that the term severe is a measure of intensity: thus a severe adverse 876 
event is not necessarily serious.  For example, itching for several days may be rated as severe, 877 
but may not be clinically serious.  878 
• MILD: Usually transient, requires no special treatment, and does not interfere with the 879 
participant’s daily activities.  880 
• MODERATE: Usually causes a low level of inconvenience or concern to the participant and 881 
may interfere with daily activities, but is usually ameliorated by [CONTACT_475213].  882 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic 883 
drug therapy or other treatment. 884 
8.1.5 Coding of Adverse Events  885 
Adverse events will be coded using the MedDRA dictionary.  The Medical Monitor will  review 886 
the investigator’s assessment of causality and may agree or disagree.  Both the investigator’s and 887 
Medical Monitor’s assessments will be recorded.  The Medical Monitor will have the final say in 888 
determining the causality.  889 
Adverse events that continue after the participant’s discontinuation or completion of the study 890 
will be followed until their medical outcome is determined or until no further change in the 891 
condition is expected.  892 
8.1.6 Outcome of Adverse Event  893 
The outcome of each reportable adverse event will be classified by [CONTACT_3470]:  894 
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  [ADDRESS_1162532] the AE/SAE stop date.  896 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 37 of 48 • RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized [ADDRESS_1162533] the AE/SAE stop date.  898 
• FATAL – A fatal outcome is defined as the SAE that resulted in death.  Only the event that 899 
was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the time 900 
of death; however, were not the cause of death, will be recorded as “resolved” at the time of 901 
death.  902 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as 903 
the event was ongoing with an undetermined outcome.  904 
 An ongoing outcome will require follow-up by [CONTACT_3471] 905 
outcome of the AE/SAE.  906 
 The outcome of an ongoing event at the time of death that was not the cause of death, 907 
will be updated and recorded as “resolved” with the date of death recorded as the stop 908 
date.  909 
• UNKNOWN – An unknown outcome is defined as an inability to access the participant or 910 
the participant’s records to determine the outcome (for example, a participant that was lost to 911 
follow-up). 912 
All clinically significant abnormalities of clinical laboratory measurements or adverse events 913 
occurring during the study and continuing at study termination should be followed by [CONTACT_941] 914 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the [ADDRESS_1162534] the participant until the adverse event has resolved or stabilized.  922 
8.2 Repo rtable Device Issues  923 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 924 
whether an adverse event occurred, except in the following circumstances.  925 
The following device issues are anticipated and will not be reported  but will be reported as an 926 
Adverse Event if the criteria for AE reporting described above are met:  927 
• Component disconnections 928 
• CGM sensors lasting fewer than the number of days expected per CGM labeling 929 
• CGM tape adherence issues  930 
• Pump infusion set occlusion not leading to ketosis  931 
• Battery lifespan deficiency due to inadequate charging or extensive wireless communication  932 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 38 of 48 • Intermittent device component disconnections/communication failures not leading to system 933 
replacement  934 
• Device issues clearly addressed in the user guide manual that do not require additional 935 
troubleshooting 936 
• Skin reactions from CGM sensor placement or pump infusion set placement that do  not meet [ADDRESS_1162535] be reported to the IRB per IRB reporting guidelines for this protocol. 943 
Other reportable adverse events, device malfunctions (with or without an  adverse event), and 944 
device complaints should be reported promptly by [CONTACT_666142], 945 
but there is no formal required reporting period. 946 
Upon knowledge of an UADE, the investigator  will investigate the UADE and if indicated, 947 
report the results of the investigation to the IRB , and the FDA within ten working days of the 948 
investigator  becoming aware of the UADE per 21CFR 812.46(b) (2). The Medical Monitor must [ADDRESS_1162536] receipt notice of the UADE.  953 
In the case of a device system component malfunction (e.g. pump, CGM, control algorithm), 954 
information will be forwarded to the responsible company by [CONTACT_14523], to be handled 955 
by [CONTACT_837338] t system.  956 
8.5 Stoppi[INVESTIGATOR_2121]  957 
8.5.1 Participant Discontinuation of Study Device  958 
Rules for discontinuing study device use are described below. 959 
• The investigator believes it is unsafe for the participant to continue on the intervention.  This 960 
could be due to the development of a new medical condition or worsening of an existing 961 
condition; or participant behavior contrary to the indications for use of the device that 962 
imposes on the participant’s safety  963 
• The participant requests that the treatment be stopped  964 
• Participant pregnancy  965 
• One epi[INVESTIGATOR_28546] 966 
• One severe hypoglycemia event as defined in section [IP_ADDRESS]  967 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 39 of 48 If pregnancy occurs, the participant will be discontinued from the study entirely. Otherwise, even 968 
if the study device system is discontinued, the participant will be encouraged to remain in the 969 
study through the final study visit. 970 
8.5.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396]  971 
In the case of a system malfunction resulting in a severe hypoglycemia or severe hyperglycemia 972 
event (as defined in section  [IP_ADDRESS]), use of the study device system will be suspended while the 973 
problem is diagnosed. 974 
In addition, study activities could be similarly suspended if the manufacturer of any constituent 975 
study device requires stoppage of device use for safety reasons (e.g. product recall).  The [ADDRESS_1162537] suspension of study activities or stoppage 981 
of the study if deemed necessary based on the totality of safety data available.  982 
8.6 Risks 983 
The potential risks associated with use of the study device are described in section 1.3. 984 
Additional risks are minor and/or infrequent and include: 985 
• Pain, bruising, redness, or infection from blood draws 986 
• Loss of confidentiality 987 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 40 of 48 Chapter 9:  Miscellaneous Considerations  [ADDRESS_1162538] their personal 992 
physician to change their prescribed personal insulin to lispro or aspart for the duration of the 993 
trial. 994 
Treatment with any non -insulin glucose-lowering agent (including GLP-1 agonists, Symlin, 995 
DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals) will be [ADDRESS_1162539] be approved by [CONTACT_837339] 997 
initiation of study equipment. 998 
The investigational study devices (t:slim X2 insulin pump, study CGM s ystems) must be 999 
removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) or diathermy 1000 
treatment. Participants may continue in the trial after temporarily discontinuing use if requiring 1001 
one of the treatments above.  1002 
9.3 Participant Compensation 1003 
Participants will not receive compensation or reimbursement for his/her participation in this 1004 
study. 1005 
9.4 Participant Withdrawal 1006 
Participation in the study is voluntary, and a participant may withdraw at any time.  1007 
For participants who withdraw, their data will be used up until the time of withdrawal.  1008 
9.5 Confidentiality 1009 
For security and confidentiality purposes, participants will be assigned an identifier that will 1010 
be used instead of their name .  De -identified participant information may also be provided to 1011 
Tandem for system evaluation purposes. 1012 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 41 of 48 Chapter 10:  Statistical Consideration  [ADDRESS_1162540] tabulation of data by [CONTACT_1570] 1016 
(ie, for DSMB review).  The analysis plan synopsis in this chapter contains the framework of the 1017 
anticipated final analysis plan.  1018 
10.2 Statistical Hypotheses 1019 
The hypotheses for the primary outcome are:  1020 
a. Null Hypothesis : the use of MyTDI results in a decreased percentage of the time spent 1021 
between 70 -180mg/dL during home use 1022 
b. Alternative Hypothesis  : the use of MyTDI does not results in a decreased percentage of 1023 
the time spent between 70 -180mg/dL during home use 1024 
All outcomes will be analyzed using repeated measure ANOVA between baseline and the 1025 
studied period, using within-between factors.  1026 
We will compute all outcome for baseline, camp, and the final home segment. Outcomes will be 1027 
further refined to focus on daytime (7am-11pm), nighttime (11pm-7am), and for the Ski 1028 
Admission, ski time (9am -noon & 1:30pm-4:30) [ADDRESS_1162541] size of 0.25 using repeated measure ANOVA and a within- 1031 
between comparison (baseline – home, grouped by [CONTACT_3148]), assuming 0.75 correlation 1032 
between measurements. With N=[ADDRESS_1162542] to reach 85% power, allowing for up to 2 1033 
participants (10%) to fail to complete the study.  1034 
10.4 Outcome Measures  1035 
10.4.1  Primary Efficacy Endpoint  1036 
The primary outcome for this study is the percent of time spent between 70mg/dL and 180mg/dL 1037 
as computed by [CONTACT_837340] 1038 
available CGM values. CGM gaps inferior to 3 hours will be linearly interpolated  1039 
10.4.2  Secondary Efficacy Endpoints  1040 
Additional CGM outcomes will include:  1041 
• Percent CGM below 50mg/dL 1042 
• Percent CGM below 54mg/dL 1043 
• Percent below 60mg/dL 1044 
• Percent CGM below 70mg/dL 1045 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 42 of 48 • Percent CGM above 180mg/dL 1046 
• Percent CGM above 250mg/dL 1047 
• Percent CGM above 300mg/dL: 1048 
• Average CGM 1049 
• CGM coefficient of variation  1050 
• CGM based LBGI & HBGI 1051 
Furthermore, we will compute  1052 
• Total amount of insulin used  1053 
• Number of Hypoglycemic epi[INVESTIGATOR_837333] 70mg/dL 1054 
• Number of rescue CHO 1055 
• Total amount of rescues CHO  1056 
[IP_ADDRESS]  Safety Analyses  1057 
All randomized participants will be included in these analyses and the circumstances of all 1058 
reportable cases of the following will be summarized and tabulated by [CONTACT_1570]:  1059 
• Severe hypoglycemia 1060 
• Diabetic ketoacidosis  1061 
• Other serious adverse events and serious a dverse device events  1062 
• Unanticipated adverse device effects  1063 
10.5 Device Issues  1064 
The following tabulations and analyses will be performed by [CONTACT_418103] 1065 
issues:  1066 
• Device malfunctions requiring study team contact [CONTACT_91120]  1067 
• Sensor performance metrics (difference, absolute relative difference, and International 1068 
Organization for Standardization criteria) – if applicable, by [CONTACT_91121]. 1069 
• % time CGM data available -  overall and by [CONTACT_24473] 1070 
The following tabulations will be perfo rmed for the CLC arm only: 1071 
• Performance metrics, describing the Control -IQ system and its components like:  1072 
 % time CGM data were available to the Control-IQ system – overall and by [CONTACT_24473] 1073 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 43 of 48  % time in different operational modes per week - overall and by [CONTACT_24473]  1074 
 Rate of different failure events and alarms per 24  hours recorded by [CONTACT_418104]-IQ 1075 
system – overall and by [CONTACT_24473] 1076 
 1077 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 44 of 48 Chapter 11:  Data Collection and Monitoring  1078 
11.1 Case Report Forms and Device Data 1079 
The main study data are collected through a combination of case report forms (CRFs) and [ADDRESS_1162543] ions are to be developed by [CONTACT_779] 1099 
and implemented promptly.   The site PI/study staff is responsible for knowing and adhering to 1100 
their IRB requirements.   1101 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 45 of 48 Chapter 12:  Ethics/Protection of Human Participants  [ADDRESS_1162544] 1103 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1104 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 1105 
21 CFR Part 56, and/or the ICH E6. 1106 
12.2 Institutional Review Boards 1107 
The protocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_1162545] be obtained before any participant is enrolled.  Any amendment to the protocol will 1110 
require review and approval by [CONTACT_3484].  All 1111 
changes to the consent form will be IRB approved; a determination will be made regarding 1112 
whether previously consented participants need to be re-consented.  1113 
12.3 Inform ed Consent Process  1114 
12.3.1  Consent Procedures and Documentation  1115 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 1116 
the study and continues throughout the individual’s study participation.  Extensive discussion of [ADDRESS_1162546] all documents and records required to 1134 
be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or 1135 
hospi[INVESTIGATOR_307]) for the participants in this study.  The clinical study site will permit access to such 1136 
records. 1137 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 46 of 48 The study participant’s contact [CONTACT_738766] f or internal use during the 1138 
study.  At the end of the study, all records will continue to be kept in a secure location for as long 1139 
a period as dictated by [CONTACT_46202]. 1140 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 47 of 48 Chapter 13:  References  1141 
1.  Anderson SM, Raghinaru D, Pi[INVESTIGATOR_45905], et al. Multinational Home Use of Closed -Loop 1142 
Control Is Safe and Effective. Diabetes Care 2016;39:1143-50. [ADDRESS_1162547] hypoglycemia during exercise in 1145 
type 1 diabetes. Diabetes Technol Ther 2014;16:[ADDRESS_1162548], Forlenza GP, et al. Closed-Loop Control During Intense 1147 
Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski 1148 
Study. Diabetes Care 2017;40:1644-50. 1149 
4.  Breton MD, Patek SD, Lv D, et al. Continuous Glucose Monitoring and Insulin Informed 1150 
Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability 1151 
in Type 1 Diabetes Mellitus. Diabetes Technol Ther 2018;20:[ADDRESS_1162549], DeBoer MD, Keith-Hynes P, et al. Use of an artificial pancreas among 1153 
adolescents for a missed snack bolus and an underestimated meal bolus. Pediatr Diabetes 1154 
2016;17:28-35. [ADDRESS_1162550] E, Kovatchev BP, et al. Pi[INVESTIGATOR_837334] 1156 
Pancreas in Type 1 Diabetes. Diabetes Care 2012;35:e65 -e7. 1157 
7.  DeBoer MD, Breton MD, Wakeman C, et al. Performance of an Artificial Pancreas 1158 
System for Young Children with Type 1 Diabetes. Diabetes Technol Ther 2017;19:293-8. [ADDRESS_1162551], Topchyan K, Kovatchev BP, Francis GL, Breton MD. 1160 
Heart rate informed artificial pancreas system enhances glycemic control during exercise in 1161 
adolescents with T1D. Pediatr Diabetes 2017;18:540 -6. 1162 
9.  Del Favero S, Boscari F, Messori M, et al. Randomized Summer Camp  Crossover Trial 1163 
in 5- to 9-Year -Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. 1164 
Diabetes Care 2016;39:1180-5. [ADDRESS_1162552], Breton MD, DeBoer MD. Improving the 1166 
Safety and Functionality of an Artificial Pancreas System for Use in Younger Children: Input 1167 
from Parents and Physicians. Diabetes Technol Ther 2017;19:660-74. 1168 
11.  Keith -Hynes P, Guerlain S, Mize B, et al. DiAs user interface: a patient -centric interface 1169 
for mobile artificial pancreas systems. J Diabetes Sci Technol 2013;7:[ADDRESS_1162553] J. The Diabetes Assistant: A Smartphone-Based 1171 
System for Real-Time Control of Blood Glucose. Electronics 2014;3:609. [ADDRESS_1162554] E, Cobelli C, et al. Fea sibility of outpatient fully integrated 1173 
closed -loop control: first studies of wearable artificial pancreas. Diabetes Care 2013;36:[ADDRESS_1162555] E, Cobelli C, et al. Safety of outpatient closed -loop control: first 1175 
randomized crossover tr ials of a wearable artificial pancreas. Diabetes Care 2014;37:1789 -96. 1176 
15.  Kovatchev B, Cheng P, Anderson SM, et al. Feasibility of Long-Term Closed -Loop 1177 
Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery. Diabetes Technol 1178 
Ther 2017;19:18-24. 1179 
UNIVERSITY OF VIRGINIA  
180030 – Winter Study 2019 v1.4 Page 48 of 48 16.  Ly TT, Buckingham BA, DeSalvo DJ, et al. Day -and-Night Closed-Loop Control Using 1180 
the Unified Safety System in Adolescents With Type 1 Diabetes at Camp. Diabetes Care. United 1181 
States2016:e106-7. [ADDRESS_1162556] J, Robert A, Ben Brahim N, et al. DiAs  web monitoring: a real -time remote 1183 
monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Technol 1184 
2013;7:1427-35. 1185 
18.  Sanchez-Pena R, Colmegna P, Garelli F, et al. Artificial Pancreas: Clinical Study in Latin 1186 
America Without  Premeal Insulin Boluses. J Diabetes Sci Technol 2018;12:914-25. 1187 
19.  Thabit H, Hovorka R. Coming of age: the artificial pancreas for type 1 diabetes. 1188 
Diabetologia 2016;59:1795-805. 1189 
20.  Troncone A, Bonfanti R, Iafusco D, et al. Evaluating the Experience of Children With 1190 
Type 1 Diabetes and Their Parents Taking Part in an Artificial Pancreas Clinical Trial Over 1191 
Multiple Days in a Diabetes Camp Setting. Diabetes Care 2016;39:[ADDRESS_1162557] E, Kovatchev B, et al. Mul ticenter closed -loop insulin delivery study 1193 
points to challenges for keepi[INVESTIGATOR_657937] a safe range by a control algorithm in adults 1194 
and adolescents with type 1 diabetes from various sites. Diabetes Technol Ther 2014;16:613-22 1195 
 1196 